EW
ADPT icon

Evoke Wealth’s Adaptive Biotechnologies ADPT Stock Holding History

Evoke Wealth’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-537
Closed -$7K – 1160
2022
Q1 		$7K Hold
537
– – ﹤0.01% 823
2021
Q4 		$15K Hold
537
– – ﹤0.01% 721
2021
Q3 		$18K Hold
537
– – ﹤0.01% 649
2021
Q2 		$22K Buy
+537
New +$20.9K ﹤0.01% 636

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Evoke Wealth's ADPT Position: Q2 2022 in Review

Evoke Wealth sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 537 shares — an estimated $7K sold.

Evoke Wealth first reported a position in ADPT in Q2 2021 and held it in 4 quarters. The position peaked at $22K in Q2 2021. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

  • Evoke Wealth reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • Evoke Wealth sold 537 Adaptive Biotechnologies shares in Q2 2022, an estimated $7K.
  • Evoke Wealth first reported a position in Adaptive Biotechnologies in Q2 2021 and held it in 4 quarters.
  • Evoke Wealth's Adaptive Biotechnologies position peaked at $22K in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Evoke Wealth's 13F filing for Q2 2022, filed 4 Aug 2022.